# Regenacy Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regenacy-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.regenacy.com
- Total disclosed funding: $46M
- Latest round: Series B (Jan 27, 2022)
- Investors on record: 7

## About

Regenacy Pharmaceuticals, LLC is a biotechnology company specializing in developing innovative therapies to address unmet medical needs in rare and chronic diseases.Founded in 2016 and headquartered in Waltham, US, Regenacy Pharmaceuticals focuses on advancing therapeutics for rare diseases. The company has executed 2 deals, with the most recent being a Series B funding round on January 27, 2022, raising USD 7.81 mn led by Cobro Ventures alongside 3E Bioventures Capital, Taiwania Capital, and Yonjin Venture. CEO Simon Jones has led the company since its inception.Regenacy Pharmaceuticals primarily concentrates on developing a range of therapies aimed at treating rare and chronic diseases. Its product pipeline includes innovative treatments that address significant medical challenges, enhancing patient outcomes and improving quality of life. The company collaborates with various stakeholders in the healthcare ecosystem to deliver these specialized solutions.The company's revenue model is centered around funding for R&D initiatives and partnerships that leverage its therapeutic innovations. Revenue is primarily generated through strategic collaborations and licensing agreements that allow for the development and commercialization of its drug candidates. These agreements are designed to ensure a sustainable income stream while furthering the company’s research and development goals.Regenacy Pharmaceuticals plans to utilize the USD 7.81 mn raised in Series B funding to accelerate the development of its product pipeline and expand into new therapeutic areas. The company is actively designing new therapies aimed for clinical trials in the next 12-18 months, with a focus on rare diseases. Additionally, there are plans to expand its market presence into Europe and parts of Asia by 2024, enhancing its global footprint and accessibility to its innovations.

## Funding rounds

- Series B, Jan 27, 2022, $7.8M — Cobro Ventures, 3E Bioventures Capital, Taiwania Capital, Yonjin Venture
- Series A, Mar 24, 2020, $38M — Yonghua Capital, Cobro Ventures, Taya Venture Capital, 3E Bioventures Capital, Taiwania Capital, Viva Biotech Holdings

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Cobro Ventures (https://capitalatlas.ai/funds/cobro-ventures) — Series A, Series B
- Taya Venture Capital (https://capitalatlas.ai/funds/taya-venture-capital) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A, Series B
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series A, Series B
- Viva Biotech Holdings — Series A
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series B